US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

More patients come forward with stories about the pains they've suffered since beginning Ozempic, joining a growing number of ...

Hanmi and Eli Lilly began a development and marketing deal in 2015 for the drug. Lilly received worldwide rights to the molecule for all indications excluding China, Hong Kong, Taiwan, and Korea.

As Chief Commercial Officer at Zoetis, Jamie Brannan will lead an evolved commercial organizational structure that will ...

About Eli Lilly and Company and Novo Nordisk A/S Eli Lilly and Company ... the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, ...

Eli Lilly logo is shown on one of the company's offices in San ... The new investment, which will bring the company's cumulative investment in China to exceed 20 billion yuan ($2.81 billion), aims to ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Eli Lilly's weight loss drug sales in Q3 weren't as strong as it anticipated. Its earnings will continue to grow at a rapid pace regardless. It still has a couple of levers it can pull to drive ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy according to Billionaire Ken Fisher. Ken Fisher is a prominent ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low volatility stocks. We will also discuss the latest updates around the market and ...